Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium chloride 0.9% and potassium chloride 0.3% in plastic container provides isotonic crystalloid solution for resuscitation and maintenance of extracellular fluid volume. Sodium chloride restores sodium and chloride deficits, while potassium chloride replenishes potassium, essential for maintaining cellular membrane potential, nerve conduction, and muscle contraction, including cardiac function.
Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.
Maintenance of fluid and electrolyte balance,Replacement of sodium and chloride deficits,Treatment and prevention of hypokalemia,Intravenous fluid resuscitation
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis),Adjunctive therapy in acute bronchial asthma and status asthmaticus,Off-label: Treatment of apnea of prematurity
Intravenous infusion, rate and volume determined by clinical need: typical adult dose is 1-2 L/day for maintenance or replacement, up to 3-4 L/day for deficits; maximum infusion rate 1 L/hour under continuous monitoring. Contains 0.9% sodium chloride (154 m Eq/L Na+, Cl-) and 0.3% potassium chloride (40 m Eq/L K+).
Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.
Sodium and chloride: 6–12 hours (tissue distribution equilibrium); potassium: 12–24 hours (slow exchange from intracellular stores). Clinical context: half-life prolonged in renal impairment.
Terminal elimination half-life: 3-12 hours in adults (mean 5-6 hours); prolonged in hepatic impairment, heart failure, COPD, and neonates (up to 30 hours). Smoking reduces half-life by 30-50%.
Not metabolized; sodium and potassium are excreted primarily by the kidneys.
Theophylline is metabolized primarily in the liver by cytochrome P450 isoenzymes, predominantly CYP1A2, with minor contributions from CYP2E1 and CYP3A4. Metabolism involves N-demethylation and oxidation. In neonates, metabolism is immature; in adults, ~90% is hepatically cleared. Ethylenediamine is minimally metabolized.
Renal: >95% as chloride and sodium ions; potassium ions also excreted renally (90% reabsorbed, remainder excreted). Biliary/fecal: negligible (<5%).
Renal excretion of unchanged drug (about 10-20%) and metabolites (primarily 1,3-dimethyluric acid, 1-methyluric acid, 3-methylxanthine). Billary/fecal excretion is negligible.
Sodium, chloride, potassium: not protein bound (0% binding).
Theophylline (active moiety): approximately 40% bound to plasma proteins, primarily albumin. Protein binding decreases in neonates, hepatic cirrhosis, and uremia.
Sodium/chloride: 0.15–0.25 L/kg (extracellular fluid); potassium: 4–5 L/kg (total body water, with preferential intracellular distribution). Clinical meaning: sodium distributes mainly in plasma and interstitial fluid; potassium distributes extensively into cells.
Apparent volume of distribution: approximately 0.4-0.6 L/kg (average 0.45 L/kg). Indicates distribution into total body water; slightly higher in neonates and premature infants.
Intravenous: 100%. Not administered orally; enteral absorption would be 100% but is not a relevant route for this formulation.
Oral: 96-100% for immediate-release tablets; 50-70% for some sustained-release formulations depending on formulation. Rectal: 70-80% (variable). IV: 100%.
Contraindicated in anuria or severe renal impairment (GFR <30 m L/min) due to risk of hyperkalemia and fluid overload. For GFR 30-60 m L/min, use with caution, monitor serum potassium and renal function; reduce infusion rate by 50% if required. In acute kidney injury, avoid use unless guided by serum electrolytes.
No dose adjustment required for GFR >30 m L/min. For GFR 10-30 m L/min: reduce maintenance dose by 50% and monitor serum theophylline levels. For GFR <10 m L/min: reduce maintenance dose by 50% and extend dosing interval or use with caution.
No specific dose adjustment for Child-Pugh A or B; use cautiously in Child-Pugh C due to risk of fluid overload and electrolyte disturbances. Monitor potassium levels closely, as hepatic impairment may affect potassium regulation.
Child-Pugh A: reduce dose by 50%. Child-Pugh B: reduce dose by 75%. Child-Pugh C: contraindicated or use with extreme caution, reduce dose by 80% and monitor levels.
Weight-based: infants and children: maintenance 100-120 m L/kg/day for first 10 kg, plus 50 m L/kg/day for next 10 kg, plus 20 m L/kg/day for each additional kg; for deficits, replace based on losses. Maximum rate 10 m L/kg/hour (but limited by potassium content to 0.5 m Eq/kg/hour). Use only if potassium deficit confirmed and renal function normal.
Loading dose: 1 mg/kg IV (if not on theophylline). Maintenance: Continuous infusion: age 6 months-1 year: 0.5 mg/kg/h; age 1-9 years: 0.8 mg/kg/h; age 9-12 years: 0.7 mg/kg/h; age 12-16 years: 0.6 mg/kg/h. Maximum daily dose: 24 mg/kg/day.
Use with caution due to age-related renal impairment and fluid overload risk. Initiate at lower rates (e.g., 1 m L/kg/hour) and titrate based on clinical and electrolyte monitoring. Monitor serum potassium closely as hyperkalemia is more common. Reduce total daily volume by 30-50% in patients with congestive heart failure or chronic kidney disease.
Consider lower initial doses due to decreased clearance. Use ideal body weight. Start at lower maintenance infusion rate (e.g., 0.3 mg/kg/h) and titrate based on serum levels and clinical response. Monitor for toxicity.
No FDA black box warning.
None
Risk of hyperkalemia, especially in patients with renal impairment,Risk of fluid overload in patients with congestive heart failure or renal insufficiency,Monitor serum electrolytes and renal function,Avoid rapid infusion to prevent hyperkalemia-induced cardiac arrest
Narrow therapeutic index; serum theophylline levels must be monitored to avoid toxicity. Risk of seizures, cardiac arrhythmias, and death, especially at high serum concentrations. Caution in patients with hepatic impairment, congestive heart failure, cor pulmonale, fever, and in the elderly. Drug interactions with cimetidine, fluoroquinolones, macrolides, oral contraceptives, and other CYP1A2 inhibitors can increase toxicity.
Hyperkalemia,Hypernatremia,Fluid overload states (e.g., heart failure, pulmonary edema),Severe renal impairment with oliguria or anuria,Concurrent use of potassium-sparing diuretics or ACE inhibitors that increase potassium levels
Absolute: Hypersensitivity to theophylline, ethylenediamine, or any component; use in patients with active seizure disorder (unless receiving appropriate anticonvulsant therapy); use in patients with a history of ventricular arrhythmias (except under close supervision). Relative: Peptic ulcer disease, hyperthyroidism, hypertension, and renal impairment.
Avoid high-potassium foods (e.g., bananas, oranges, tomatoes, potatoes, spinach, avocados, dried fruits) and potassium-containing salt substitutes unless directed by a physician. Dietary potassium intake should be consistent to avoid fluctuations.
Avoid large amounts of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they can potentiate theophylline effects and increase risk of toxicity. A high-protein diet may increase theophylline clearance; maintain consistent dietary habits.
Sodium chloride and potassium chloride are physiologic ions; no teratogenic effects are expected at therapeutic doses. Hypo- or hypernatremia/hyperkalemia may pose fetal risks indirectly. No specific trimester risks identified with proper electrolyte balance.
Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only if benefit outweighs risk; may cause fetal tachycardia or irritability due to adenosine receptor blockade. Avoid near term due to potential neonatal irritability.
Sodium and potassium are normal constituents of breast milk; supplementation does not significantly alter milk composition. M/P ratio not applicable as these are endogenous ions. Considered compatible with breastfeeding at recommended doses.
Not recommended unless essential. Aminophylline is excreted into breast milk; M/P ratio approximately 0.6–0.8. Monitor infant for irritability or insomnia. Consider alternative therapies if breastfeeding.
Pregnancy may increase plasma volume, but no dose adjustment for normal replacement. Adjustments only for specific electrolyte imbalances; standard infusion rates remain unchanged.
Pregnancy may decrease protein binding and increase clearance of theophylline; monitor serum levels closely. Dose may need to be increased by 10–30% to maintain therapeutic levels. Postpartum, doses may need reduction.
This solution is used for maintenance fluid therapy in patients with hypokalemia or to prevent potassium depletion, especially when NPO. Monitor serum potassium and renal function; contraindicated in severe renal impairment, hyperkalemia, or conditions with potassium retention. Infuse via central line if concentration exceeds 40 m Eq/L. Use with caution in patients on ACE inhibitors, ARBs, or potassium-sparing diuretics.
Aminophylline is a bronchodilator used primarily for asthma and COPD exacerbations. Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Administer IV infusion over 30 minutes to avoid hypotension. Caution in patients with cardiac arrhythmias, hyperthyroidism, or seizure disorders. Drug interactions include cimetidine, fluoroquinolones, and macrolides which increase theophylline levels.
Report any muscle weakness, cramps, or irregular heartbeat immediately.,This medication contains potassium; do not take additional potassium supplements or salt substitutes without consulting your doctor.,Inform your healthcare provider about all medications you are taking, especially heart or blood pressure medicines.,You may experience burning at the IV site; report any pain, redness, or swelling.
Take this medication exactly as prescribed; do not stop or change dose without consulting your doctor.,Avoid excessive caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects like jitteriness and palpitations.,Report any symptoms of toxicity such as nausea, vomiting, insomnia, rapid heart rate, or seizures immediately.,Inform your healthcare provider of all other medications, especially antibiotics, heart medications, or seizure drugs.,Do not chew or crush the solution; it is for intravenous use only under medical supervision.
"Atracurium besylate, a nondepolarizing neuromuscular blocking agent, may enhance the ulcerogenic potential of oral potassium chloride by reducing gastrointestinal motility and increasing local contact time of the potassium chloride tablet with the gastric and intestinal mucosa. This prolonged exposure can heighten the risk of gastrointestinal erosion, bleeding, or perforation, particularly in patients with pre-existing lesions or receiving high-dose potassium supplementation. Clinically, this interaction necessitates close monitoring for signs of gastrointestinal injury when these agents are coadministered."
"Methscopolamine bromide, an anticholinergic agent, reduces gastrointestinal motility and delays gastric emptying, which can prolong the contact time of orally administered Potassium chloride (KCl) tablets or capsules with the gastric mucosa. This increased exposure to high concentrations of potassium in the gastrointestinal tract potentiates the local ulcerogenic effect of KCl, leading to a higher risk of esophageal, gastric, or intestinal erosions, ulcers, hemorrhage, perforation, or stricture formation. Clinically, this interaction may present with dysphagia, epigastric pain, hematemesis, melena, or signs of acute abdomen."
"Fesoterodine, an anticholinergic agent used for overactive bladder, can reduce gastric motility and prolong gastrointestinal transit time. This effect may increase the local contact time of potassium chloride tablets with the gastrointestinal mucosa, potentiating the ulcerogenic risk of potassium chloride, which can cause esophageal or intestinal ulceration, stenosis, or perforation. The interaction is clinically significant in patients with pre-existing gastrointestinal motility disorders or those taking high-dose potassium supplements."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is a Electrolyte that works by Sodium chloride 0.9% and potassium chloride 0.3% in plastic container provides isotonic crystalloid solution for resuscitation and maintenance of extracellular fluid volume. Sodium chloride restores sodium and chloride deficits, while potassium chloride replenishes potassium, essential for maintaining cellular membrane potential, nerve conduction, and muscle contraction, including cardiac function.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine. Theophylline acts as a non-selective phosphodiesterase inhibitor, increasing intracellular cyclic AMP levels, leading to bronchodilation. It also blocks adenosine receptors, stimulates catecholamine release, and enhances diaphragmatic contractility. The ethylenediamine component increases solubility.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is: Intravenous infusion, rate and volume determined by clinical need: typical adult dose is 1-2 L/day for maintenance or replacement, up to 3-4 L/day for deficits; maximum infusion rate 1 L/hour under continuous monitoring. Contains 0.9% sodium chloride (154 m Eq/L Na+, Cl-) and 0.3% potassium chloride (40 m Eq/L K+).. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Loading dose: 5-6 mg/kg IV over 20-30 minutes (if not on theophylline). Maintenance: 0.5-0.7 mg/kg/h IV continuous infusion.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.3% IN PLASTIC CONTAINER is classified as Category A/B. Sodium chloride and potassium chloride are physiologic ions; no teratogenic effects are expected at therapeutic doses. Hypo- or hypernatremia/hyperkalemia may pose fetal risks indi. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Pregnancy Category C. First trimester: Limited human data; animal studies show no teratogenicity but some developmental delays at high doses. Second and third trimesters: Use only . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.